The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey

Uzunkopru, Cihat; Tutuncu, Melih; Gunduz, Tuncay; GÜMÜŞ, HALUK; Sen, Sedat; Demir, Serkan; ÇİNAR, BİLGE; TÜRE, HATİCE; Uygunoglu, Ugur; Togrol, Rifat; TERZİ, MURAT; Kurtuncu, Murat; ÖZAKBAŞ, SERKAN; Tutuncu, Mesude; BECKMANN, YEŞİM; Siva, Aksel

doi:10.1111/ijcp.14158

The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey

Uzunkopru C., Tutuncu M., Gunduz T., GÜMÜŞ H., Sen S., Demir S., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.75, sa.7, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 75 Sayı: 7
Basım Tarihi: 2021
Doi Numarası: 10.1111/ijcp.14158
Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.